Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
ConditionPartial Lipodystrophy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age12+
SponsorAmryt Pharma
About this trial
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Eligibility criteria
Qualifiers
Confirmed diagnosis of familial or acquired partial lipodystrophy
Disqualifiers
Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.
Trial design
Treatments tested in this trial
- Metreleptin
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov